Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?

Pouplard C, Desconclois C, Sobas F, Aillaud MF, Ternisien C, Caron C.

Int J Lab Hematol. 2015 Feb;37(1):125-32. doi: 10.1111/ijlh.12253. Epub 2014 May 12.

PMID:
24815078
2.
3.

Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.

Kershaw GW, Chen LS, Jayakodi D, Dunkley SM.

Thromb Res. 2013;132(6):735-41. doi: 10.1016/j.thromres.2013.09.018. Epub 2013 Sep 21.

PMID:
24119613
4.

Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation.

Salvagno GL, Astermark J, Ekman M, Franchini M, Guidi GC, Lippi G, Poli G, Berntorp E.

Haemophilia. 2007 Jan;13(1):51-6.

PMID:
17212725
5.

The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.

Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novákovà I.

Thromb Haemost. 2001 Dec;86(6):1435-9.

PMID:
11776311
7.

VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.

Berntorp E.

Haemophilia. 2007 Dec;13 Suppl 5:69-72. doi: 10.1111/j.1365-2516.2007.01577.x.

PMID:
18078401
8.

The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.

Shi Q, Schroeder JA, Kuether EL, Montgomery RR.

J Thromb Haemost. 2015 Jul;13(7):1301-9. doi: 10.1111/jth.13001. Epub 2015 Jun 11.

PMID:
25955153
9.

[Modified Bethesda, modified Nijmegen and blank assays for coagulation factor VIII inhibitor detection and factors affecting the results].

Feng HM, Li Q, Xu WS, Chen DM, Zheng L.

Nan Fang Yi Ke Da Xue Xue Bao. 2016 Apr;36(4):592-5. Chinese.

PMID:
27113194
10.

Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.

Veyradier A, Caron C, Ternisien C, Wolf M, Trossaert M, Fressinaud E, Goudemand J.

Haemophilia. 2011 Nov;17(6):944-51. doi: 10.1111/j.1365-2516.2011.02499.x. Epub 2011 Mar 3.

PMID:
21371195
11.

Haemophilia A and von Willebrand's disease.

Goodeve AC, Rosén S, Verbruggen B.

Haemophilia. 2010 Jul;16 Suppl 5:79-84. doi: 10.1111/j.1365-2516.2010.02303.x. Review.

PMID:
20590861
12.

Measurement of von Willebrand factor-FVIII binding activity in patients with suspected von Willebrand disease type 2N: application of an ELISA-based assay in a reference laboratory.

Zhukov O, Popov J, Ramos R, Vause C, Ruden S, Sferruzza A, Dlott J, Sahud M.

Haemophilia. 2009 May;15(3):788-96. doi: 10.1111/j.1365-2516.2009.01995.x. Epub 2009 Feb 27.

PMID:
19298374
13.

DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.

Casonato A, Dannhauser D, Pontara E, Bertomoro A, Orazi B, Santarossa L, Zerbinati P, Girolami A.

Blood Coagul Fibrinolysis. 1996 Jul;7(5):549-53.

PMID:
8874865
14.

Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen.

Verbruggen B, van Heerde WL, Laros-van Gorkom BA.

Semin Thromb Hemost. 2009 Nov;35(8):752-9. doi: 10.1055/s-0029-1245107. Epub 2010 Feb 18. Review.

PMID:
20169511
15.
16.

In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.

Tagariello G, Zanotto D, Radossi P, Sartori R, Belvini D, Salviato R.

Am J Hematol. 2007 Jun;82(6):460-2.

17.

Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.

Mannucci PM, Shi Q, Bonanad S, Klamroth R.

Haemophilia. 2014 Sep;20 Suppl 6:2-16. doi: 10.1111/hae.12465. Review. Erratum in: Haemophilia. 2014 Sep;20(5):e376.

PMID:
24975700
18.

Comparative measurement of FVIII inhibitors in hemophilia A patients using ELISA and the Bethesda assay.

Kim SY, Kang SY, Lee WI.

Korean J Lab Med. 2010 Jun;30(3):260-3. doi: 10.3343/kjlm.2010.30.3.260.

19.

[Comparison of modified Bethesda assay and Nijmegen assay in detecting FVII inhibitor in patients with hemophilia A].

Fan LK, Wang ZW, Hua BL, Su W, Wang SJ, Zhao YQ.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009 Oct;31(5):551-4. Chinese.

Items per page

Supplemental Content

Write to the Help Desk